Non-invasive detection of allele-specific CRISPR-SaCas9-KKH disruption of TOR1A DYT1 allele in a xenograft mouse model.

IF 6.1 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular Therapy. Nucleic Acids Pub Date : 2025-01-28 eCollection Date: 2025-03-11 DOI:10.1016/j.omtn.2025.102466
Katia E Maalouf, Dawn Madison Frederick, Nutan Sharma, Edwina Abou Haidar, Tianhe Xiao, Justin Seungkyu Han, Mohammed S Mahamdeh, Roy J Soberman, David Rufino-Ramos, Benjamin P Kleinstiver, Hyder A Jinnah, Christine A Vaine, D Cristopher Bragg, Koen Breyne
{"title":"Non-invasive detection of allele-specific CRISPR-SaCas9-KKH disruption of <i>TOR1A</i> DYT1 allele in a xenograft mouse model.","authors":"Katia E Maalouf, Dawn Madison Frederick, Nutan Sharma, Edwina Abou Haidar, Tianhe Xiao, Justin Seungkyu Han, Mohammed S Mahamdeh, Roy J Soberman, David Rufino-Ramos, Benjamin P Kleinstiver, Hyder A Jinnah, Christine A Vaine, D Cristopher Bragg, Koen Breyne","doi":"10.1016/j.omtn.2025.102466","DOIUrl":null,"url":null,"abstract":"<p><p>DYT1 dystonia is a neurological movement disorder characterized by a dominant 3-base pair deletion (ΔGAG) in the <i>TOR1A</i> gene. This study demonstrates a gene-editing approach that selectively targets the ΔGAG mutation in the <i>TOR1A</i> DYT1 allele while safeguarding the wild-type (WT) <i>TOR1A</i> allele. We optimized an adeno-associated virus (AAV) vector-compatible variant of the <i>Staphylococcus aureus</i> Cas9 nuclease ortholog (SaCas9-KKH) in DYT1 patient-derived human neuronal progenitor cells (hNPCs). On-target editing of the <i>TOR1A</i> DYT1 allele was confirmed at the genomic level from brain tissue in a xenograft mouse model. To avoid brain biopsy for demonstrating <i>TOR1A</i> DYT1 editing, we developed a non-invasive monitoring method using extracellular RNA (exRNA). <i>TOR1A</i> exRNA was retrieved from the extracellular vesicle (EV) secretions of hNPCs and plasma samples, indicating whether the donor was a <i>TOR1A</i> DYT1 carrier. This technique enabled us to assess AAV-mediated disruption of the <i>TOR1A</i> DYT1 allele in the brains of mice using blood samples.</p>","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":"36 1","pages":"102466"},"PeriodicalIF":6.1000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925580/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2025.102466","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/11 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

DYT1 dystonia is a neurological movement disorder characterized by a dominant 3-base pair deletion (ΔGAG) in the TOR1A gene. This study demonstrates a gene-editing approach that selectively targets the ΔGAG mutation in the TOR1A DYT1 allele while safeguarding the wild-type (WT) TOR1A allele. We optimized an adeno-associated virus (AAV) vector-compatible variant of the Staphylococcus aureus Cas9 nuclease ortholog (SaCas9-KKH) in DYT1 patient-derived human neuronal progenitor cells (hNPCs). On-target editing of the TOR1A DYT1 allele was confirmed at the genomic level from brain tissue in a xenograft mouse model. To avoid brain biopsy for demonstrating TOR1A DYT1 editing, we developed a non-invasive monitoring method using extracellular RNA (exRNA). TOR1A exRNA was retrieved from the extracellular vesicle (EV) secretions of hNPCs and plasma samples, indicating whether the donor was a TOR1A DYT1 carrier. This technique enabled us to assess AAV-mediated disruption of the TOR1A DYT1 allele in the brains of mice using blood samples.

异种移植小鼠模型中TOR1A DYT1等位基因特异性CRISPR-SaCas9-KKH破坏的无创检测
DYT1肌张力障碍是一种以TOR1A基因显性3碱基对缺失(ΔGAG)为特征的神经运动障碍。该研究展示了一种选择性靶向TOR1A DYT1等位基因ΔGAG突变的基因编辑方法,同时保护野生型(WT) TOR1A等位基因。我们在DYT1患者来源的人神经祖细胞(hNPCs)中优化了金黄色葡萄球菌Cas9核酸酶同源物(SaCas9-KKH)的腺相关病毒(AAV)载体兼容变体。在异种移植小鼠模型的脑组织中,在基因组水平上证实了TOR1A DYT1等位基因的靶向编辑。为了避免脑活检来证明TOR1A DYT1编辑,我们开发了一种使用细胞外RNA (exRNA)的非侵入性监测方法。从hNPCs的细胞外囊泡(EV)分泌物和血浆样本中提取TOR1A exRNA,判断供者是否为TOR1A DYT1携带者。这项技术使我们能够使用血液样本评估aav介导的小鼠大脑中TOR1A DYT1等位基因的破坏。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
15.40
自引率
1.10%
发文量
336
审稿时长
20 weeks
期刊介绍: Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信